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        In contrast to other organs, the liver appears 
more resistant to autoimmune damage caused 
by local mechanisms of tolerance induction via 
T cell deletion, inactivation, and apoptosis (  1  –  4  ). 
Nevertheless, autoimmune liver diseases com-
prising a variety of immune-mediated disorders, 
such as primary biliary cirrhosis (PBC), primary 
sclerosing cholangitis, and autoimmune hepatitis 
(AIH), do exist and often cause severe long-term 
consequences. The resulting syndromes partially 
overlap, and clinical signs and symptoms are of-
ten inconsistent and variable, making a defi  nite 
diagnosis sometimes diffi   cult (  5  –  7  ). Infections are 
prime candidates for initiating autoimmunity in 
genetically predisposed individuals because they 
frequently induce strong infl  ammatory responses 
in various organs and can attract a multitude of 
potentially autoaggressive lymphocytes to the site 
of infection (  8  ). To evaluate whether virus infec-
tions can break tolerance to liver autoantigens, 
we infected mice with adenovirus Ad5 express-
ing human cytochrome P450 2D6 (Ad-2D6), 
which constitutes the major human autoantigen 
in type 2 AIH (AIH-2) (  9, 10  ). Cytochrome P450 
2D6 (CYP2D6) is recognized by type 1 liver 
kidney microsomal antibodies (LKM-1s), which 
are present in up to 10% of chronic hepatitis C 
virus (HCV)  –  infected patients (  11  ) and are the 
hallmark defi  ning AIH-2 patients (  6, 7  ). 
  One possible mechanism by which viruses 
could induce autoimmunity is a structural simi-
larity of virus and host components, a phe-
nomenon commonly referred to as   “  molecular 
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  Autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cirrho-
sis, often have severe consequences for the patient. Because of a lack of appropriate animal 
models, not much is known about their potential viral etiology. Infection by liver-tropic 
viruses is one possibility for the breakdown of self-tolerance. Therefore, we infected mice 
with adenovirus Ad5 expressing human cytochrome P450 2D6 (Ad-2D6). Ad-2D6  –  infected 
mice developed persistent autoimmune liver disease, apparent by cellular infi  ltration, 
hepatic fi  brosis,   ”  fused  ”   liver lobules, and necrosis. Similar to type 2 AIH patients, Ad-2D6  –
  infected mice generated type 1 liver kidney microsomal  –  like antibodies recognizing the 
immunodominant epitope WDPAQPPRD of cytochrome P450 2D6 (CYP2D6). Interestingly, 
Ad-2D6  –  infected wild-type FVB/N mice displayed exacerbated liver damage when com-
pared with transgenic mice expressing the identical human CYP2D6 protein in the liver, 
indicating the presence of a stronger immunological tolerance in CYP2D6 mice. We demon-
strate for the fi  rst time that infection with a virus expressing a natural human autoantigen 
breaks tolerance, resulting in a chronic form of severe, autoimmune liver damage. Our 
novel model system should be instrumental for studying mechanisms involved in the initia-
tion, propagation, and precipitation of virus-induced autoimmune liver diseases. 1410 ANIMAL MODEL FOR AUTOIMMUNE LIVER DISEASE | Holdener et al.
only very few cells were still expressing GFP (  Fig. 1 A  ). Simi-
lar expression kinetics for GFP were detected in Ad-GFP  –
  infected wild-type FVB/N mice (not depicted). Upon infection 
of FVB/N and CYP2D6 mice with either Ad-2D6 or Ad-
GFP, all mice developed transient hepatic damage character-
ized by an elevation of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) serum levels (  Fig. 1 B  ). Val-
ues reached up to 150 and 250 U/liter of serum for AST and 
ALT, respectively, from weeks 1 to 5 after infection. The se-
rum aminotransferase regressed to normal, preinfection levels 
around week 6 after Ad-2D6 or Ad-GFP infection (  Fig. 1 B  ). 
Statistical evaluation of the augmentation over time after in-
fection revealed that there was no signifi  cant diff  erence be-
tween mice that have been infected with Ad-2D6 and Ad-GFP 
and between FVB/N and CYP2D6 mice (  Fig. 1 B  ). There is, 
however, a nonsignifi  cant tendency toward an earlier increase 
in both AST and ALT in mice that have been infected with 
Ad-2D6. Further, we measured alkaline phosphatase (AP) as a 
cholestasis marker and found a minor increase at weeks 1 and 
2 after infection with Ad-2D6 but not with Ad-GFP (  Fig. 1 C  ). 
As observed for AST and ALT, this elevation was only tran-
sient and no signifi  cant increase in AP levels was found at 
week 4 or later, indicating that no persistent biliary obstruc-
tion or cholangitis occurred after infection of mice with either 
Ad-2D6 or Ad-GFP. No acute or persistent elevation of      
glutamyl transpeptidase (GGT) levels was detected in infected 
FVB/N and CYP2D6 mice (not depicted). In summary, these 
data indicate that adenovirus infection by itself results in acute 
but transient hepatocellular damage. 
  Infection with Ad-2D6 results in severe and persistent 
liver damage 
  To assess the potential for virally triggered autoimmune  –
  mediated liver damage, both humanized CYP2D6 mice and 
FVB/N littermates were infected with 2   ×   10  10   particles of 
Ad-2D6 (or Ad-GFP), and livers were removed at several 
times after infection. In contrast to the infection of mice with 
Ad-GFP, Ad-2D6 infection resulted in severe and persistent 
liver damage. Morphologically, livers of Ad-2D6  –  infected 
mice showed several features characteristic for liver damage 
associated with autoimmune-mediated liver disease and/or 
chronic viral hepatitis, such as fused liver lobes, hyperplasic 
nodules, and capsular fi  brosis (  Fig. 2 A  ).   Importantly, none of 
these morphological changes occurred in Ad-GFP  –  infected 
mice. To semiquantitatively evaluate the morphological ap-
pearance, we defi  ned a liver damage score (LDS;   Fig. 2 B  ). 
LDS was determined over a period of 45 wk for both CYP2D6 
and FVB/N mice infected with either Ad-2D6 or Ad-GFP 
(  Fig. 2 C  ). Interestingly,   >  50% of wild-type mice already 
developed the fi  rst morphological signs of liver damage at 
week 1 after infection with Ad-2D6, whereas mice express-
ing CYP2D6 showed obvious signs of liver damage only at 
week 2 after Ad-2D6 infection (  Fig. 2 C  , left). However, no 
signifi  cant diff  erence in the overall LDS between transgenic 
and wild-type mice was detected at later times (  Fig. 2 C  , left). 
Importantly, LDS was persistently elevated in both CYP2D6 
mimicry  ”   (  12  ). It has been demonstrated in the past that molec-
ular mimicry may be involved in the induction, acceleration, 
and prevention of autoimmune processes (  13  –  17  ). Interest-
ingly, the occurrence of LKM-1s in chronic HCV  –  infected 
patients might be explained by molecular mimicry, because 
antibodies recognizing the HCV proteins NS3 and NS5a 
recognize a specifi  c conformational epitope on CYP2D6 be-
tween aa 254 and 288 (  18  ). Furthermore, HCV has the po-
tential to induce autoreactive CD8 T cells, which cross react 
with the cytochrome P450 isoforms 2A6 and 2A7 that con-
tain sequence homology to HCV aa 178  –  187 (  19  ). Indeed, 
antibodies to CYP2A6 have been found in HCV-infected 
patients (  20  ). Importantly, LKM-1s of AIH-2 patients recog-
nizing CYP2D6 aa 193  –  212 have been demonstrated to cross 
react with epitopes of HCV (RNA-dependent DNA poly-
merase NS5 aa 2977  –  2996) and CMV (alkaline exonuclease aa 
121  –  140) (  21  ). A further sequence homology has been reported 
between the immunodominant CYP2D6 epitope, DPAQP-
PRD, and the infected cell protein 4 (ICP4) of HSV-1 (  22  ). 
However, defi  nite proof for environmental factors, such as 
viruses, as inducers of human autoimmune liver disease has 
been elusive. 
  Thus, we wished to test, as a proof of principle, whether 
viral infl  ammation caused by liver-tropic adenovirus can facil-
itate the breaking of tolerance to a naturally occurring autoan-
tigen in the liver. This concept has been previously shown in 
several diabetes models in which virally meditated infl  amma-
tion provided a   “  fertile fi  eld  ”   for autoimmune reactions, for 
example the RIP-LCMV mouse (  8, 23  ) and Ins-HA mouse 
(  24  ). For the present study, we have chosen the human auto-
antigen CYP2D6 as a target antigen. We generated Ad-2D6 
and infected nontransgenic FVB/N and transgenic CYP2D6 
mice, expressing human CYP2D6 under the control of its 
own promoter as a self-antigen in the liver (  25  ). The use of 
such an Ad-2D6 vector system ensured both a high expression 
rate of the triggering antigen (CYP2D6) in the liver (antigen-
specifi  c initiation) and a potent activation of the immune sys-
tem by viral infection. We found that infection with Ad-2D6 
results in two distinct phases of liver damage: an acute, antivi-
ral phase, characterized by transient elevation of serum amino-
transferase levels and minor cellular infi  ltrations, followed by 
an autoimmune phase characterized by massive hepatocellular 
damage, strong cellular infi  ltration, formation of high titer anti-
CYP2D6 antibodies, and extensive hepatic fi  brosis. 
    RESULTS   
  Infection of mice with adenovirus results in transient 
hepatic damage 
  Transgenic CYP2D6 mice and nontransgenic FVB/N litter-
mates were infected with 2   ×   10  10   particles of adenovirus Ad5 
expressing GFP (Ad-GFP), the liver was removed at diff  erent 
days after infection, and expression of GFP was examined un-
der a fl  uorescence microscope (  Fig. 1 A  ).   GFP-expressing cells 
were detected from day 1 after infection and reached a maxi-
mal number at day 7 after infection, when GFP expression 
was detected throughout the liver. At day 14 after infection, JEM VOL. 205, June 9, 2008 
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both size and number (  Fig. 3 A  , middle row), and at week 8 
nearly no focal points of lymphocyte accumulation were de-
tectable in Ad-GFP  –  treated mice, leaving behind only some 
scattered lymphocytes (  Fig. 3 A  , bottom row, far left). In 
contrast, Ad-2D6  –  infected mice had a massive increase in 
infl  ammation and liver cell destruction at week 8. Interface 
hepatitis with extensive infi  ltrates in the periportal and paren-
chymal regions could be detected, and areas of focal necrosis 
were growing larger and confl  uent (  Fig. 3 A  , bottom row). 
Semiquantitative analysis of the obtained cellular infi  ltration 
data revealed a signifi  cant persistence in CYP2D6 and FVB/
N mice at week 8 after Ad-2D6 infection when compared 
with Ad-GFP  –  infected mice (  Fig. 3 B  ). In FVB/N mice, a 
signifi  cant diff  erence was even found starting from week 4 
after infection, suggesting an accelerated liver damage in 
wild-type mice (  Fig. 3 B  ). Immunohistochemical analysis 2 
wk after infection revealed that the cellular infi  ltrates con-
sisted predominantly of B cells (B220  +   cells), CD4 T cells, 
and macrophages (F4/80  +   cells;   Fig. 3 C  ). In contrast, only a 
few CD8 T cells were found (  Fig. 3 C  ). In support of our 
initial observation (  Fig. 2  ), we found that FVB/N mice had 
more rapid cellular infi  ltration compared with transgenic 
CYP2D6 mice (  Fig. 3 C  ). Liver sections of Ad-2D6  –  infected 
FVB/N mice already displayed a degree of cellular infi  ltra-
tion similar to that observed in CYP2D6 livers at weeks 4 
and FVB/N mice even at times later than 3 mo after infection 
(  Fig. 2 C  , left). Note that with some minor exceptions, no 
morphological signs of liver damage were detected in mice 
infected with Ad-GFP (  Fig. 2 C  , right). However, statistical 
evaluation revealed that the LDS was signifi  cantly diff  erent 
between Ad-2D6  –   and Ad-GFP  –  infected CYP2D6 as well 
as FVB/N mice (P   <   0.05 using the Mann-Whitney test). 
These data demonstrate that although only a transient elevation 
of ALT, AST, and AP was detected after adenovirus infection 
of CYP2D6 or FVB/N mice, the viral expression of CYP2D6 
resulted in persistent liver damage. 
  Ad-2D6  –  infected mice show massive infi  ltration 
and fi  brosis 
  Histological examination of liver sections at various times af-
ter infection of CYP2D6 and FVB/N mice with either Ad-
2D6 or Ad-GFP revealed an early infl  ammatory phenotype 
induced by both Ad-2D6 and Ad-GFP (  Fig. 3 A  , top row).   
This initial infl  ammation is likely caused by the direct anti-
viral immune response mounted to eliminate the infectious 
agent. However, later on the immunopathology diff  ered be-
tween Ad-2D6  –   and Ad-GFP (control)  –  infected animals. At 
week 4, the areas of focal necrosis were becoming larger and 
increased in number in Ad-2D6  –  treated mice, whereas Ad-
GFP  –  infected mice showed a reduction of focal necrosis in 
    Figure 1.         Phase 1: acute liver damage by adenovirus infection.   (A) Expression of GFP in liver sections at several times after infection of CYP2D6 
mice with Ad-GFP. Bars, 50   μ  m. (B) Serum levels of ALT and AST in humanized CYP2D6 and wild-type FVB/N mice infected with Ad-2D6 or Ad-GFP at 
several times after infection. Note that elevations in serum ALT and AST were transient and not persistent. Statistical evaluation (  t   test) revealed no sig-
nifi  cant differences in AST and ALT augmentation curves over time between Ad-2D6  –   and Ad-GFP  –  infected mice (FVB, P = 0.7 [ALT] and 0.79 [AST]; 
CYP2D6, P = 0.5 [ALT] and 0.13 [AST]) and between FVB/N and CYP2D6 mice (Ad-2D6, P = 0.64 [ALT] and 0.59 [AST]; Ad-GFP, P = 0.31 [ALT] and 0.82 [AST]). 
(C) Serum levels of AP in humanized CYP2D6 and wild-type FVB/N mice infected with Ad-2D6 or Ad-GFP at several times after infection (  n   = 5 per group). 
Transient AP elevation was detected in CYP2D6 and FVB/N mice at weeks 1 and 2 after infection with Ad-2D6 but not Ad-GFP. Statistical evaluation 
(  t   test) revealed signifi  cant differences in serum AP compared with preinfection levels (week 1, P = 0.035 [FVB/N Ad-2D6]; week 2, P = 0.044 [FVB/N 
Ad-2D6] 0.029 [CYP2D6 Ad-2D6]) and between Ad-2D6  –   and Ad-GFP  –  infected mice (week 1, P = 0.03 [FVB] and 0.063 [CYP2D6]; week 2, P = 0.055 [FVB] 
and 0.029 [CYP2D6]). Data are mean   ±   SD.     1412 ANIMAL MODEL FOR AUTOIMMUNE LIVER DISEASE | Holdener et al.
Tissue sections covering the entire liver from three to fi  ve 
mice per experimental group have been analyzed, and a rep-
resentative picture is displayed for each time point (  Fig. 4 A  ). 
An increase in subcapsular fi  brosis over time was found in 
Ad-2D6  –  infected Ad-2D6 and FVB/N mice only (  Fig. 4 A  ), 
whereas no diff  erence was found in Ad-GFP  –  infected mice 
(  Fig. 4 A  ). Interestingly, the development of subcapsular 
fi  brosis was accelerated and more pronounced in wild-type 
FVB/N mice (  Fig. 4 A  ). For a better visualization of the pre-
dominantly subcapsular and interlobular fi  brosis, we per-
formed a reconstruction of an immunofl  uorescent staining of 
a representative liver section of a CYP2D6 mouse at week 8 
after Ad-2D6 infection, covering the entire organ (  Fig. 4 B  ). 
The fi  gure shows the massive subcapsular fi  brosis and the in-
terlobular collagen I deposits that   “  glue  ”   the individual lobes 
(including the left and right medial as well as the left lateral 
lobes) together. No signifi  cant collagen I deposits were found 
in Ad-GFP  –  infected mice (  Fig. 4 B  , inset). Costaining for 
B220  +   cells demonstrates that many cellular infi  ltrates are 
located in close proximity to the subcapsular collagen I deposits 
(  Fig. 4 B  , regions 1 and 2). Similar results have been obtained 
for Ad-2D6  –  infected FVB/N mice (unpublished data). These 
data indicate that Ad-2D6, in contrast to Ad-GFP, induces a 
persistent damage of the liver in both CYP2D6 and FVB/N 
mice. Further, the fi  nding that cellular infi  ltration is aug-
mented (  Fig. 3 B  ) and development of fi  brosis is accelerated 
(  Fig. 4 A  ) in wild-type FVB/N mice indicates the existence 
of partial tolerance in CYP2D6 mice. 
  B cell tolerance to the self-target antigen is broken 
in CYP2D6 mice 
  Next, we wanted to evaluate the immunological mechanism 
responsible for the observed liver damage. We collected blood 
of CYP2D6 and FVB/N mice infected with 2   ×   10  10   par-
ticles of Ad-2D6 or Ad-GFP at various times after infection 
and determined the activation state of B cells and the titers of 
anti-CYP2D6 antibodies. We used either a goat anti  –  mouse 
pan-Ig antibody or recombinant human CYP2D6 protein 
to capture total Ig or anti-CYP2D6 antibodies produced by 
activated B cells in a B cell ELISPOT assay (  Fig. 5 A  ).   No 
striking diff  erences in the frequency of Ig-producing cells of 
FVB/N or CYP2D6 mice infected either with Ad-2D6 or 
Ad-GFP were observed (  Fig. 5 B  , top). In contrast, B cells 
secreting specifi  c anti-CYP2D6 antibodies were exclusively 
generated in Ad-2D6  –  infected mice (  Fig. 5 B  , bottom). The 
highest frequency of anti-CYP2D6 antibody-secreting cells 
of     0.01% of all splenocytes was found at week 4 after in-
fection (  Fig. 5 B  ). Interestingly, FVB/N mice generated a 
higher number of anti-CYP2D6 antibody-secreting cells than 
CYP2D6 mice (  Fig. 5 B  ). These data were mainly refl  ected 
in the titer of anti-CYP2D6 antibodies in the serum. IgM-
type anti-CYP2D6 antibodies were found to a similar extent 
in FVB/N and CYP2D6 mice after infection with Ad-2D6, 
but not Ad-GFP, and reached a maximum titer of 500  –  900 
between weeks 2 and 4 after infection (  Fig. 5 C  ). In con-
trast, IgG-type anti-CYP2D6 antibodies reached titers up to 
and 8 after infection at week 2 after infection, whereas the 
livers of CYP2D6 mice showed only minor infi  ltrates at 
week 2 after Ad-2D6 infection (  Fig. 3 C  ). Liver fi  brosis 
was detected exclusively in Ad-2D6  –  infected mice, as dem-
onstrated by Sirius red staining of collagen fi  bers (  Fig. 4 A  ) 
and immunohistochemistry using an FITC-conjugated anti  –
  collagen I antibody (  Fig. 4 B  ).   Sirius red staining was performed 
with liver sections of CYP2D6 and FVB/N mice obtained at 
various times after infection with either Ad-2D6 or Ad-GFP. 
    Figure 2.         Phase 2: persistent liver damage after infection of mice by 
Ad-2D6.   (A) Paraformaldehyde-fi  xed livers of CYP2D6 mice infected with 
either Ad-2D6 or Ad-GFP at week 8 after infection. Bars, 0.5 cm. (B) LDS for 
evaluation of the morphological appearance of mouse liver after adenovirus 
infection. Pictures of representative livers of LDS 0 (Ad-GFP infected) and 
LDS 5 (Ad-2D6 infected) are shown in A. (C) Livers of CYP2D6 and FVB/N 
mice infected with either Ad-2D6 or Ad-GFP were harvested at several times 
after infection, and LDS was determined by morphological examination. The 
mean LDS for each group is indicated by horizontal lines. Note that Ad-
2D6  –  infected mice only develop persistent liver damage. Statistical analysis 
(Mann-Whitney test) revealed signifi  cant differences between Ad-2D6 and 
Ad-GFP mice at the indicated times. *, P   <   0.01; **, P   <   0.05.    JEM VOL. 205, June 9, 2008 
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CYP2D6 mice did not reach as high titers as FVB/N mice 
(  Fig. 5 C  ) fi  ts well with our previous results (as reported ear-
lier in this paper), in which CYP2D6 mice showed a lower 
frequency of anti-CYP2D6 antibody-secreting B cells and 
had attenuated hepatocellular damage and fi  brosis compared 
  >  500,000 in Ad-2D6  –  infected FVB/N mice and increased 
with time until around week 6 after infection (  Fig. 5 C  ). We 
could not detect any CYP2D6-specifi  c IgE-type antibodies 
in CYP2D6 or FVB/N mice infected with Ad-2D6 or Ad-
GFP (unpublished data). The fi  nding that Ad-2D6  –  infected 
    Figure 3.         Hepatic necrosis and massive cellular infi  ltrations after Ad-2D6-infection.   (A) Hematoxylin and eosin staining of liver sections ob-
tained from CYP2D6 and FVB/N mice infected with either Ad-2D6 or Ad-GFP at weeks 1, 4, and 8 after infection. Note that persistent hepatic damage 
(massive cellular infi  ltrations and signifi  cant necrosis) is present in Ad-2D6  –  infected mice only. Infection of FVB/N mice with Ad-GFP results in a similar 
histology as Ad-GFP infection of CYP2D6 mice (not depicted). Bars, 50   μ  m. (B) The following scoring system was used to assess liver infi  ltration: 0, no 
visible infi  ltration; 1, few focal infi  ltrates; 2, numerous scattered focal infi  ltrates; 3, few large clusters of infi  ltrating cells (perivascular or subcapsular); 
4, numerous large clusters of infi  ltrating cells occupying   >  50% of portal tracts or central veins; and 5, confl  uent periportal infi  ltrates. The presented data 
are mean infi  ltration scores   ±   SEM. Statistical analysis (Mann-Whitney test) revealed signifi  cant differences between mice infected with Ad-2D6 or Ad-
GFP at the indicated times after infection. *, P   <   0.05. The number of individual mouse livers analyzed per experimental group is indicated at the bottom 
of each data column. (C) Immunohistochemistry of liver sections of wild-type FVB/N and humanized CYP2D6 mice at week 2 after infection with Ad-2D6. 
Cellular infi  ltrations consisted predominantly of B cells (B220), CD4 T cells, and macrophages (F4/80). Bars, 50   μ  m.     1414 ANIMAL MODEL FOR AUTOIMMUNE LIVER DISEASE | Holdener et al.
from patients with PBC (antimitochondrial antibodies) or 
AIH-1 (antinuclear antibodies [ANAs]), respectively (  Fig. 5 D  ). 
  Anti-CYP2D6 antibodies in Ad-2D6  –  infected mice 
and sera from AIH-2 patients recognize an identical 
immunodominant epitope 
  Similar to patients with AIH-2, who generate LKM-1s, 
Ad-2D6  –  infected mice generated high titers of anti  –  human 
with wild-type FVB/N mice. For further characterization, 
we compared the staining patterns of rat liver sections by the 
sera of Ad-2D6  –  infected mice with the sera of patients with 
various autoimmune liver diseases. A similar LKM-1  –  like 
staining pattern was found for the sera from Ad-2D6  –  infected 
mice (CYP2D6 and FVB/N mice) and the sera of AIH-2 
patients (  Fig. 5 D  ). This pattern was clearly diff  erent from the 
mitochondrial or nuclear staining pattern seen with the sera 
    Figure 4.         Subcapsular fi  brosis after infection of mice with Ad-2D6 but not Ad-GFP.   (A) Sirius red staining of collagen fi  bers in the subcapsular 
region of the liver at several times after infection of CYP2D6 and FVB/N mice with either Ad-2D6 or Ad-GFP. Tissue sections covering entire livers from 
three to fi  ve mice per experimental group were analyzed, and a representative picture of the subcapsular region is displayed for each time point. Note 
the increase in magnitude of collagen deposition in Ad-2D6  –  infected mice over time and the accelerated subcapsular fi  brosis in FVB/N compared with 
CYP2D6 mice. Bars, 20   μ  m. (B) Reconstruction of a large section of an Ad-2D6  –  infected CYP2D6 mouse liver (week 8 after infection), including the left 
medial (LM) and right medial (RM) lobes and the left lateral (LL) lobe, stained for collagen I (green). Note the subcapsular fi  brosis and the individual lobes 
that are glued together by collagen I deposit. (inset) Reconstruction of the left lateral lobe of an Ad-GFP  –  infected CYP2D6 mouse liver (week 8 after in-
fection). Bars, 0.1 cm. Regions 1  –  4 are shown at a higher magnifi  cation. In addition to staining for collagen I (green), staining for B cells (B220  +  ; red) was 
overlaid. Regions 1 and 2 show B cells entrapped in pockets within the collagen I deposits in the subcapsular region of the liver. Regions 3 and 4 show 
areas where two or three individual liver lobes are joined by collagen I fi   bers.  Bars,  50   μ m.   JEM VOL. 205, June 9, 2008 
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shows an example of a serum of an Ad-2D6 –  infected CYP2D6 
mouse reacted with the SPOTs membrane.   Linear epitopes 
reacting with the serum are clearly visible and can be easily 
quantifi  ed (  Fig. 6 B  , top). Interestingly, sera from all Ad-2D6  –
  infected CYP2D6 as well as FVB/N mice predominantly 
CYP2D6 antibodies. Thus, we next mapped the dominant 
human CYP2D6 B cell epitope recognized by the sera of Ad-
2D6  –  infected mice by using the SPOTs technology, in which 
staggered peptides covering the entire human CYP2D6 se-
quence are covalently linked to a nylon membrane.   Fig. 6 A   
    Figure 5.         Activation of CYP2D6-specifi  c B cells and generation of anti-CYP2D6 antibodies after Ad-2D6-infection.   (A) Pictures of represen-
tative end results of total IgG or CYP2D6-specifi  c spot-forming assays. Colored spots indicate the reaction of enzyme-labeled secondary antibodies 
against secreted IgG and represent one antibody-secreting cell. (B) Quantifi  cation of total IgG (top) and CYP2D6-specifi   c  IgG  (bottom) – secreting  cells  per 
10  6   splenocytes in FVB/N and CYP2D6 mice at the time points indicated. Note that B cells secreting CYP2D6 antibody  –  specifi  c antibodies were only de-
tectable after Ad-2D6 infection. ND, not detectable. (C) IgM and IgG type anti-CYP2D6 antibody generation in FVB/N and CYP2D6 mice infected with 
either Ad-2D6 or Ad-GFP over time. Data are mean   ±   SEM. (D) Representative pictures of rat liver sections stained with sera from Ad-2D6  –  infected 
CYP2D6 mice, Ad-2D6  –  infected FVB/N mice, AIH-1 patients (ANA), AIH-2 patients (LKM-1), and PBC patients (antimitochondrial antibodies), followed by 
Alexa Fluor 488  –  conjugated anti  –  mouse IgG or FITC-conjugated anti  –  human IgG secondary antibody. Bars, 50   μ  m.     1416 ANIMAL MODEL FOR AUTOIMMUNE LIVER DISEASE | Holdener et al.
dominant CYP2D6 B cell epitope (  Fig. 6, B [bottom] and C  ). 
In addition to the immunodominant CYP2D6 aa 262  –  270 epi-
tope, other epitopes were recognized by FVB/N and CYP2D6 
mouse sera as well, although to a much lesser extent and with 
some variation between individual mice (  Fig. 6 C  ). However, 
the overall pattern of epitope recognition was mostly over-
lapping between sera from Ad-2D6  –  infected mice and patients 
with AIH-2, but not with the sera of patients with other auto-
immune liver diseases (  Fig. 6 C  ). 
  In summary, our data suggest that the breakdown of B cell 
tolerance to human CYP2D6 in transgenic CYP2D6 mice 
induced by infection with adenovirus results in autoimmune 
reactivity that is very similar to that found in AIH-2 patients. 
  reacted to a cluster of overlapping peptides within the core 
aa sequence WDPAQPPRD (CYP2D6 aa 262  –  270;   Fig. 6, B 
and C  ). It was previously reported that the majority of LKM-1 
sera reacted with a similar region of the CYP2D6 molecule 
(  22, 26  –  28  ). Most importantly, in an extensive study with the 
sera of 26 LKM-1  –  positive AIH-2 patients, 22 recognized a 
33-aa segment of CYP2D6 in this region, and 11 (50%) of 
these sera recognized the minimal B cell epitope DPAQP-
PRD (CYP2D6 aa 263  –  270) (  22  ). Indeed, in our hands four 
out of four patients with AIH-2 recognized the WDPAQP-
PRD core sequence (  Fig. 6, B [second from bottom] and C  ). 
In contrast, sera from patients with other autoimmune liver 
diseases (AIH-1 and PBC) did not recognize the immuno-
    Figure 6.         Mouse anti-CYP2D6 antibodies and sera of AIH-2 patients recognize the identical immunodominant CYP2D6 epitope.   (A)  SPOTs 
membrane containing staggered peptides of 12 aa in length covering the entire 497 aa of the human CYP2D6 molecule. The membrane was developed 
with serum of an Ad-2D6  –  infected CYP2D6 mouse. Numbers indicate the position within the CYP2D6 sequence of the fi  rst aa of the fi  rst peptide spot in 
each horizontal lane. (B) Quantifi  cation of the serum reactivity profi  le to SPOTs peptides. Representative serum samples of an Ad-2D6  –  infected CYP2D6 
mouse, an Ad-2D6  –  infected FVB/N mouse, an AIH-2 patient, and an AIH-1 patient. Numbers indicate the aa position within the human CYP2D6 sequence. 
(C) For an overview of the epitope profi  le, the human CYP2D6 sequence was divided into 20 25-aa-long sections, as indicated at the top of each column. 
Signal intensities of sera from Ad-2D6  –  infected CYP2D6 and FVB/N mice, patients with AIH-2, and patients with other autoimmune liver diseases, such as 
AIH-1, AIH-3, or PBC, are indicated in red (strong), orange (medium), gray (low), and white (no reactivity). Note that the region containing the immuno-
dominant WDPAQPPRD epitope (region 251  –  275) is recognized by all sera of Ad-2D6  –  infected CYP2D6 and FVB/N mice, as well as by all tested sera of 
AIH-2 patients, but not by sera from patients with other autoimmune liver diseases.     JEM VOL. 205, June 9, 2008 
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CYP2D6 and IL-12 resulted in signifi  cant infl  ammation in the 
liver. In addition, only minor elevations in serum ALT and a 
transient generation of low-titer anti-CYP2D6 antibodies with 
large interindividual diff  erences were stated (  41  ). 
  A common hypothesis to explain the etiology of autoim-
mune disease is genetic predisposition of the host (intrinsic 
risk factors) paired with environmental triggers (  8  ). Many au-
toimmune diseases have been associated with pathogen infec-
tion (for reviews see references   8, 42, 43  ). To date no fi  rm 
proof for environmental factors, such as viruses, as inducers 
or enhancers of most human autoimmune diseases, including 
human AIH, has been found. Direct evidence for viruses to 
induce or accelerate autoimmune disease is, however, hard to 
come by because (a) virus infections are often   “  hit and run  ”   
events that leave no traces behind at the time of diagnosis of 
autoimmune disease; (b) patients suff  ering from autoimmune 
diseases, as well as healthy individuals, undergo several patho-
gen infections during their lifetime; (c) viruses might not 
directly induce autoimmune disease but instead accelerate a 
preexisting autoimmune condition to progress to clinical dis-
ease; (d) the exact time, location, and magnitude of infection 
might be important; and (e) some pathogens have even been 
demonstrated to have protective properties (  44, 45  ). How-
ever, several pathogens have been associated with autoim-
mune liver disease. For PBC, it has been suggested that 
the xenobiotic-metabolizing bacterium   Novosphingobium aro-
maticivorans   might be involved in the initiation of the diseases 
(  46  ). For AIH, several studies implicate viruses, such as mea-
sles virus, hepatitis viruses, CMV, and Epstein-Barr virus, in 
its initiation (for reviews see   6, 47  ). In particular, sequence 
homology has been reported between the immunodominant 
CYP2D6 epitope DPAQPPRD and ICP4 of HSV-1 (  22  ). 
Further, a study by Kerkar et al. demonstrates that a consider-
able fraction of AIH-2 patients (12 out of 13, or 93%) and 
LKM-1  –  positive patients with chronic HCV infection (5 of 
10, or 50%) carry antibodies reacting to the CYP2D6 epitope 
RLLDLA (aa 204  –  209) (  21  ). Interestingly, this reactivity can 
be neutralized by incubation with epitopes of HCV (RNA-
dependent DNA polymerase NS5 aa 2977  –  2996 containing 
the core sequence RLLDLS) and CMV (alkaline exonuclease 
aa 121  –  140 containing the core sequence RLLDLA), sug-
gesting a possibility of molecular mimicry as a mechanism in-
volved in the etiology of AIH (  21  ). 
  As a proof of principle of how environmental factors can 
initiate autoimmune liver disease in an animal model, we 
used an adenovirus expressing the natural major human liver 
autoantigen CYP2D6 as a triggering factor. One has to ac-
knowledge that, in this system, large amounts of the target/
triggering protein (CYP2D6) are being expressed from the 
adenoviral vector directly in the liver in context with a sig-
nifi  cant viral infl  ammation of the target organ. Thus, our 
current fi  ndings underline the strong need for infl  ammation 
to trigger autoimmune liver damage. In our case, a hepato-
tropic adenovirus was capable of preparing a fertile fi  eld (  48  ) 
for the arrival of autoaggressive lymphocytes. It is remark-
able that, under these conditions, strong systemic induction 
Importantly, wild-type FVB/N mice, which do not express 
the human CYP2D6 model antigen but express several mouse 
Cyp isoenzymes with high homology to human CYP2D6, 
exhibit even a lesser degree of immunological tolerance to-
ward human CYP2D6 and might therefore generate an even 
stronger immune response toward human CYP2D6. 
    DISCUSSION   
  By infecting CYP2D6 humanized and wild-type FVB/N mice 
with an adenovirus vector expressing the natural human auto-
antigen CYP2D6, self-tolerance to CYP2D6 and orthologous 
mouse cytochrome P450 isoenzymes (Cyp) was broken, re-
sulting in persistent autoimmune liver damage. For the fi  rst 
time, we show the generation of autoantibodies in an animal 
model with the same specifi  city as human LKM-1s occurring in 
AIH-2 patients, combined with severe autoimmune-mediated 
hepatic damage and characterized by hepatocellular necrosis, 
massive cellular infi  ltration, and hepatic fi  brosis. 
  In theory, the liver should be a prime target for auto-
immunity. First, because of its function as a detoxifying and 
drug-metabolizing organ, cellular destruction (i.e., by ethanol) 
and neoantigen formation (i.e., protein adduct formation by 
reactive metabolites) can occur. Second, the liver is the target 
of potential environmental triggering factors for autoimmune 
disease, including hepatitis, coxsackie virus, HSV, and many 
more. It has further been suggested that the liver may act as a 
sink for activated lymphocytes (  29, 30  ). However, the fre-
quencies of autoimmune disorders that specifi  cally affl   ict the 
liver, such as AIH (  5  ), PBC (  31  ), or halothane hepatitis (  32  ), 
are relatively low when compared with other autoimmune 
diseases, such as type 1 diabetes, certain types of thyroiditis 
(Hashimoto  ’  s disease and Grave  ’  s disease), multiple sclerosis, 
or rheumatoid arthritis. In addition, it is known that liver allo-
grafts are less frequently rejected than other transplants (  33  ). 
Nevertheless, the consequences of autoimmune liver destruc-
tion are often severe, including massive hepatic damage, cirrhosis, 
and subsequent multiorgan dysfunction, which frequently makes 
liver transplantation unavoidable. Several possible explanations 
for strong hepatic tolerance have been suggested in the past, 
including T cell inactivation by antigenic priming in the liver 
(  3  ), tolerance induction via cross-presentation by liver sinu-
soidal endothelial cells (  1  ), induction of regulatory T cells by 
liver sinusoidal endothelial cells (  2  ), and hepatic stellate cell  –
  induced T cell apoptosis (  4  ). 
  Such immunosuppressive mechanisms certainly have made 
the generation of a reliable animal model to study persistent 
autoimmune-mediated liver damage diffi   cult. Although sev-
eral, mostly transgenic, mouse model systems have been tested 
in the past, only transient damage to the liver has been de-
tected in most models, such as the HBsAg (  34  –  36  ), H-2K  b   
(  37  ), ALB1-LCMV-GP33 ( 38  ), LCMV-NP ( 39  ), and TF-OVA 
models (  40  ). In addition, induction of disease often required 
the transfer of antigen-specifi  c lymphocytes (  34  –  36, 38  ). In 
another recent study, AIH-like disease was reported in mice 
by xenoimmunization using a plasmid containing the anti-
genic region of CYP2D6 (  41  ). However, only coexpression of 1418 ANIMAL MODEL FOR AUTOIMMUNE LIVER DISEASE | Holdener et al.
persistent hepatic damage follows the viral infl  ammation, but 
only when the triggering adenovirus drives the expression 
of the CYP2D6 autoantigen. Generation of anti-CYP2D6 
antibodies at very high titers was restricted to mice infected 
with Ad-2D6, whereas infection of mice transgenically ex-
pressing human CYP2D6 with Ad-GFP was not suffi   cient for 
anti-CYP2D6 antibody formation. The specifi  city of these 
antibodies was directed to the same immunodominant CYP2D6 
epitope that was recognized by LKM-1s found in the sera 
of AIH-2 patients. These data suggest that the breakdown 
of tolerance in Ad-2D6  –  infected mice might be mediated 
via a similar pathway than in patients suff  ering from AIH-2. 
It is further important to note that virus infection was neces-
sary to induce liver disease in the CYP2D6 model system. 
We injected CYP2D6 and FVB/N mice with recombi-
nant human CYP2D6 in combination with Poly-IC (i.v.), 
CpG (i.v.), or CFA (s.c.). None of these mice showed any 
signs of liver damage, such as elevated serum aminotransfer-
ases, cellular infi  ltrations, and fi  brosis. In these experiments 
only s.c. injection of recombinant human CYP2D6 emul-
sifi  ed in CFA resulted in the generation of anti-CYP2D6 
antibodies at a titer similar to Ad-2D6  –  infected mice (un-
published data). These data indicate that the generation of 
anti-CYP2D6 antibodies per se is not suffi   cient to induce auto-
immune liver damage. 
  Interestingly, wild-type FVB/N mice showed an accel-
erated course of hepatic damage with an enhanced number 
of activated CYP2D6-specifi  c B cells and generated higher 
titers of anti-CYP2D6 antibodies compared with transgenic 
CYP2D6 mice, indicating that tolerance to human CYP2D6 
is harder to overcome in CYP2D6 mice. Although, none of 
the mouse cytochrome P450 family genes (  Cyp  ) encode an 
isoenzyme with similar catalytic activity as human CYP2D6 
(  53  ), wild-type FVB/N mice do express Cyp isoenzymes with 
high sequence homology to the human CYP2D6 and other 
human CYP isoenzymes. A screening of the National Cen-
ter for Biotechnology Information databank revealed that the 
mouse Cyp isoenzymes Cyp2D9, Cyp2D11, Cyp2D22, and 
Cyp2D26 display up to 75% aa sequence homology to human 
CYP2D6 (available from GenBank/EMBL/DDBJ under ac-
cession nos.   BAE25635  ,   P24457  ,   AAF34652  ,   Q8CIM7  , and 
  M33388  , respectively). Further, the mouse Cyp2D26 protein 
contains an aa sequence (aa 262  –  270) identical to the human 
CYP2D6 epitope WDPAQPPRD, which was found to be 
immunodominant in AIH-2 patients and in Ad-2D6 –  infected 
mice. Thus, upon challenging FVB/N mice with Ad-2D6, 
autoimmune liver damage was most likely induced because 
of true molecular mimicry between the human CYP2D6 ex-
pressed via the adenovirus system and homologous mouse 
sequences (i.e., mouse Cyp2D26), as demonstrated by our 
experiments. However, tolerance to human CYP2D6 was 
more pronounced in CYP2D6 humanized mice, which ex-
press the identical human CYP2D6 molecule and exhibited 
delayed liver damage, a lower frequency of activated B cells, 
and a lower anti-CYP2D6 antibody titer. These observa-
tions allow for the speculation that similar yet not identical 
of CYP2D6-specifi  c B cells was still required, and even the 
expression of transgenic human CYP2D6 under control of 
its own promoter in CYP2D6 mice was not suffi   cient to 
break tolerance with a virus that did not express CYP2D6 
(Ad-GFP control). 
  The 2D6 isoform of the large cytochrome P450 enzyme 
family is the major antigen component specifi  cally recog-
nized by LKM-1s (  9, 10  ), which are the defi  ning hallmark 
autoantibodies present in patients affl   icted with AIH-2 (  5  –  7  ). 
AIH is a severe form of an adverse immune reaction result-
ing in the progressive destruction of the hepatic parenchyma 
(  49  ). Among AIH patients,     10% are aff  ected by AIH-2 and 
develop LKM-1s, which are regarded as serological markers 
for AIH-2. Besides LKM-1, up to 50% of AIH-2 patients de-
velop anti  –  liver cytosol type 1 antibodies, and     10% develop 
LKM-3s to family 1 uridine 5    -diphosphate glucuronosyl-
transferase (  7  ). However, the majority (90%) of AIH patients 
are aff  ected by AIH-1 and develop ANAs, anti  –  smooth muscle 
actin antibodies, atypical perinuclear antineutrophilic cyto-
plasmic antibodies, and anti  –  soluble liver antigen/liver pan-
creas antigen antibodies, which are all less well characterized 
than LKM-1s (  6, 7  ). Susceptibility factors for the individual 
AIH subtypes are dominated by the MHC haplotype, although 
other factors, such as complement genes, Igs, and TCR vari-
ants, may play a minor role as well (  6  ). In contrast to AIH-1, 
which is predominantly associated with HLA-DR3 and HLA-
DR4, AIH-2 is primarily associated with HLA-DRB1 and 
HLA-DQB1, and the presence of HLA-DR2 seems to be 
protective (for details see Krawitt [  6  ]). Autoreactive CD4 and 
CD8 T cells specifi  c for CYP2D6 have been found in the 
blood and the liver of AIH-2 patients (  50, 51  ). However, al-
though the major target antigens have been characterized on 
the level of specifi  c epitopes, the etiology of AIH-2 is only 
poorly understood. It is intriguing that the CYP2D6 anti-
gen performed well as an autoantigenic target in our model 
of adenovirally induced liver infl  ammation, underlining its 
importance in liver autoimmunity across species and under 
various conditions. Interestingly, our model system exhibited 
two phases of liver injury after infection of CYP2D6 and 
FVB/N mice with Ad-2D6. First, infection with adenovirus 
(Ad-2D6 as well as Ad-GFP) initiated an antiviral immune 
response associated with transient damage to the liver, char-
acterized by minor elevation of serum aminotransferase levels 
and focal infi  ltration by mononuclear cells. It had been pre-
viously reported (  52  ) that replication-defi  cient adenoviruses 
can induce acute injury and infl  ammation. As early as 1 h 
after infection with 10  10   particles of an adenovirus-   gal vector, 
expression of chemokines, such as macrophage infl  ammatory 
protein 2, monocyte chemoattractant protein 2, and IFN-
inducible protein 10, was strongly increased and neutrophils 
infi  ltrated immediately thereafter (  52  ). All adenovirus vectors 
tested by Muruve et al. did cause transient hepatic damage 
and cellular infi  ltrates (  52  ) similar to the focal clusters of infi  l-
trating cells we detected at day 7 for Ad-2D6 and Ad-GFP in 
our own experiments (  Fig. 3 A  ). Our crucial observation in 
this study, however, is that a second autoimmune phase with JEM VOL. 205, June 9, 2008 
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fl  ammation and breakdown of self-tolerance has been used to 
develop an animal model for myocarditis. Infection of suscep-
tible BALB/c mice with a   “  heart-passaged  ”   Coxsackie virus 
B3 containing cardiac myosin caused acute and chronic myo-
carditis similar to the human disease (  62  ). Interestingly, such 
mice quickly generated autoantibodies specifi  c for cardiac myo-
sin, suggesting that, similar to our CYP2D6 model, concomitant 
infection of and antigen delivery to the target organ breaks 
tolerance and induces disease. 
  It was the goal of our study to generate an experimental 
model for virally induced autoimmune liver disease. Infection 
with an adenovirus expressing human CYP2D6 with 75% 
sequence homology to mouse Cyp2D isoenzymes elicited 
persistent damage to the liver associated with anti-CYP2D6 
autoantibodies. A fi  rst transient phase of liver damage caused 
by the antiviral response was followed by permanent autoim-
mune liver damage. Importantly, neither TCR transgenic T 
cells nor transgenic expression of the autoantigen were re-
quired in this model, which brings it much closer to an im-
munological scenario that one could envision happening in 
human disease. Thus, our model system serves as a hallmark 
to further investigate and characterize the immunopatho-
logical mechanisms that lead to loss of tolerance to human 
autoepitopes and such a chronic hepatocellular destruction. 
Finally, such models may help to establish a basis to evaluate 
possible treatments for human autoimmune liver diseases. 
  MATERIALS AND METHODS 
  Mice and viruses.     CYP2D6 humanized mice, generated by microinjection 
of the entire human   CYP2D6   gene, including its promoter region, into the 
pronucleus of fertilized FVB/N mouse eggs to produce a transgenic mouse 
line (  25  ), were provided by F.J. Gonzalez (National Cancer Institute, 
Bethesda, MD). Wild-type FVB/NHsd mice were purchased from Harlan. 
Ad-2D6 was created by homologous recombination in   Escherichia coli   
BJ5183 between a shuttle vector containing the cDNAs for CYP2D6 and 
pAdE1       E3        (  63  ). Ad-GFP was a gift from D.J. von Seggern (The Scripps 
Research Institute, La Jolla, CA). Unless described otherwise, mice were in-
jected with a total of 2   ×   10  10   particles of Ad-2D6 or Ad-GFP (i.p. and i.v.). 
All animal experiments were approved by the local Ethics Animal Review 
Board (Darmstadt, Germany). 
  Patient sera.     All human sera were from the human serum library of the 
Department of Gastroenterology, Hepatology and Endocrinology of the 
Medizinische Hochschule Hannover and have been previously tested for 
antigen specifi  city (antimitochondrial, liver  –  kidney microsomal, and smooth 
muscle and antisoluble antibodies) by standardized immunofl  uorescence and 
competitive ELISA procedures (  64  ). All patients have been clinically diag-
nosed with either type of AIH or PBC. The blood procurement protocol 
and analysis was approved by the Ethics Committee of the Medizinische 
Hochschule Hannover. 
  Serum values for liver damage.     ALT and AST were determined by se-
rum aminotransferase enzyme activity assays (BioTron Diagnostics Inc.) using 
7.5-  μ  l mouse or human serum. ALT and AST serum levels (U/liter) were 
calculated using normal and abnormal serum standards (BioTron Diagnostics 
Inc.). AP and GGT were measured by the central laboratory of the Clinic of 
the Johann Wolfgang Goethe University. Statistical evaluation of the changes 
in ALT, AST, GGT, and AP serum levels over time after infection with Ad-
GFP or Ad-2D6 was performed by the   t   test using Prism software (version 
3.0; GraphPad Software, Inc.). P   <   0.05 was considered signifi  cant. 
autoantigens might be better targets for autoimmune reac-
tions, because central and peripheral tolerance mechanisms 
will be less effi   cient. 
  We would like to propose that molecular mimicry re-
mains one of the possible mechanisms that could become rel-
evant with a concomitant viral infection of the liver. Indeed, 
our earlier studies have shown that molecular mimicry can 
enhance an ongoing autoimmune process (  15  ), although 
cross-reactivity alone was not able to elicit autoimmune dia-
betes in naive animals. Indeed, several pathogens confer mo-
lecular mimicry with human CYP2D6. Most prominently, 
ICP4 of HSV-1 carries the peptide sequence PAQPPR, 
which is also found in the immunodominant human CYP2D6 
epitope DPAQPPRD (  22  ). However, no epidemiological as-
sociation that would link HSV-1 infection with AIH-2 has 
been reported (  22  ). In contrast, an epidemiological link was 
demonstrated for HCV infection (  54, 55  ), and antibodies to 
HCV were found in a large proportion of AIH-2 patients 
(  56, 57  ). In addition, LKM-1s were detected in up to 10% of 
HCV-infected individuals, depending on the geographic ori-
gin (  11  ). It is, however, noteworthy that LKM-1s of HCV-
infected patients recognize a diff  erent pattern of CYP2D6 
epitopes than LKM-1s of AIH-2 patients (  11, 26, 58  ), indicat-
ing a divergent pathway leading to the breakdown of toler-
ance toward CYP2D6 in HCV-infected individuals. It is 
therefore important to further analyze the mechanisms of tol-
erance breakdown to human CYP2D6 in the humanized 
CYP2D6 mouse, which generates anti-CYP2D6 antibodies 
recognizing a similar epitope pattern as human LKM-1s, and 
to analyze the kinetics of epitope recognition by the sera of 
AIH-2 patients in more detail. It is important to note that the 
CYP2D6 reactivity of LKM-1s is not restricted to the immuno-
dominant WDPAQPPRD epitope (aa 262  –  270). The de-
tection of several other CYP2D6 epitopes that have been 
recognized by various proportions of patients  ’   sera has been 
reported, including the regions aa 321  –  351, aa 373  –  389, and 
aa 410  –  429 (  26  ); aa 196  –  218 (  59  ); aa 193  –  212, aa 238  –  257, aa 
268  –  287, and aa 478  –  497 (  21  ); and aa 284  –  391, aa 412  –  429, 
and the conformational epitopes aa 1  –  146 (  60  ) and aa 321  –  379 
(  58  ). However, it seems that the outcome of these studies 
was largely dependent on the assays used and the selection of 
LKM-1 sera analyzed. It will therefore be important to dissect 
these immunoreactive epitopes in more detail to screen for 
pathogen structures conferring molecular mimicry. A very re-
cent article reports a dominant CD8 T cell reactivity to the 
HLA-A2*0201  –  restricted CYP2D6 epitope aa 245  –  254 (  61  ). 
Interestingly, aa 245  –  254  –  specifi  c CD8 T cells could be de-
tected in sections of an explanted liver of an AIH-2 patient by 
in situ MHC tetramer staining (  61  ). These data indicate that 
besides the overwhelming B cell/antibody  –  mediated immune 
response to liver autoantigens, an aggressive CD8 T cell  –
  mediated process might be involved in the pathogenesis of 
autoimmune liver diseases such as AIH-2. Thus, it will be 
important to further develop animal models refl  ecting all the 
aspects of the autoreactive immune response. In this context, 
it is noteworthy that a similar approach of virus-induced in-1420 ANIMAL MODEL FOR AUTOIMMUNE LIVER DISEASE | Holdener et al.
aa of the 12-mer peptides were shifted within the human CYP2D6 by three 
aa residues. Membranes were blocked for 6 h at room temperature in 2% 
dry milk/PBS before they were incubated overnight at 4  °  C in serum di-
luted 1:200 in wash buff  er (blocking buff  er containing 0.1% Tween 20). 
Membranes were washed four times in wash buff  er and were then incu-
bated at room temperature for 2 h with IRDye800-labeled secondary anti-
body (Rockland Immunochemicals, Inc.) diluted 1:20,000 in wash buff  er. 
After two washes in wash buff  er and three washes in PBS, fl  uorescence 
  intensity was analyzed using an infrared imaging system (Odyssey; LI-COR 
Biosciences GmbH). 
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